Is NYC a biotech hub? Gut-brain start­up Kally­ope, equipped with $66M in new mon­ey, says yes

In a win for New York City’s hope­ful biotech scene, Co­lum­bia Uni­ver­si­ty spin­out Kally­ope has nailed down a $66 mil­lion fi­nanc­ing round with plans of grow­ing the start­up’s staff in NYC’s life sci­ence core.

The com­pa­ny got the Se­ries B cash from many of the same in­vestors that con­tributed to their A round, in­clud­ing Lux Cap­i­tal, The Col­umn Group, and Il­lu­mi­na Ven­tures, among oth­ers.

Nan­cy Thorn­ber­ry

Kally­ope is led by CEO Nan­cy Thorn­ber­ry, a long­time Mer­ck vet­er­an who joined the com­pa­ny in 2015 when there was on­ly six peo­ple on staff. To­day, the com­pa­ny em­ploys 44 and plans to grow its staff to 60 by the end of this year.

The com­pa­ny is try­ing to map out the com­mu­ni­ca­tion lines be­tween the gut and the brain. They call this bi-di­rec­tion­al con­vo the “gut-brain ax­is,” and it’s made up of hor­mon­al and neur­al cir­cuits. The field is still full of mys­ter­ies, Thorn­ber­ry tells me, but re­searchers do know the sys­tem mod­u­lates phys­i­ol­o­gy and be­hav­ior. De­fects in the gut-brain cir­cuits have been linked to meta­bol­ic and gas­troin­testi­nal dis­eases, as well as CNS dis­or­ders like autism and Parkin­son’s.

“There re­al­ly has not been a com­pre­hen­sive un­der­stand­ing of the bi-di­rec­tion­al com­mu­ni­ca­tion be­tween the gut and the brain,” Thorn­ber­ry said. “To the best of my knowl­edge, we’re the first to ac­tu­al­ly have a goal of map­ping gut-brain cir­cuits and tar­get­ing them with small mol­e­cules that can be­come ther­a­peu­tics.”

The com­pa­ny has “sev­er­al” pre­clin­i­cal pro­grams un­der­way, with a fo­cus on me­tab­o­lism and CNS dis­or­ders to start. Thorn­ber­ry was mum on the de­tails but in­di­cat­ed this re­cent Se­ries B should take some of these pro­grams to the clin­ic.

The start­up has set up shop at the Alexan­dria Cen­ter for Life Sci­ences on the East Side of Man­hat­tan (a rel­a­tive­ly new biotech hub), right along­side big play­ers like Eli Lil­ly, Roche, and Nes­tle Skin Health.

Thorn­ber­ry says the city has seen a boost of life sci­ence ac­tiv­i­ty in re­cent years, thanks to ef­forts made by the state and city to in­cen­tivize biotech to plant roots in New York. To put that thought in per­spec­tive, it’s im­por­tant to note that Thorn­ber­ry is on the ad­vi­so­ry coun­cil for a $500 mil­lion eco­nom­ic de­vel­op­ment ef­fort to es­tab­lish NYC as a life sci­ence hub. And she’s rather com­mit­ted to build­ing up the city’s life sci­ence brand.

“NYC has proven to be an out­stand­ing place to re­cruit for biotech,” Thorn­ber­ry tells me. “The scene is just be­gin­ning to grow here, and so there’s an un­tapped pool of tal­ent of sci­en­tists from acad­e­mia who are in­ter­est­ed in work­ing in biotech. There’s al­so a num­ber of in­di­vid­u­als want­i­ng to make tran­si­tion from phar­ma to biotech who want to live here in New York.”

Still, Thorn­ber­ry ad­mits the city has had a his­tor­i­cal prob­lem with find­ing space for biotech.

“But the may­or and the state are mak­ing a big com­mit­ment to solve that prob­lem,” she says. “That’s re­flect­ed by a num­ber of fi­nan­cial in­cen­tives the city and state pro­vid­ed.”

NYC’s eco­nom­ic de­vel­op­ment group tells me it’s post­ed a “want­ed ad” for an or­ga­ni­za­tion or joint ven­ture to de­vel­op and op­er­ate a life sci­ence R&D cam­pus in the city. New York is putting up $100 mil­lion in city cap­i­tal and city-owned land to spur the project, which has been coined “LifeSci NYC Hub,” the EDC says.


Im­age: New York City. Shut­ter­stock

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.

But it was a perfect time for AbbVie CEO Rick Gonzalez to pick up the phone and ask Saunders if he’d like to consider a “strategic” deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

CEO Pascal Soriot via Getty Images

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.

Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.